Strategic multi-target partnership with Takeda (2019) to discover, develop and commercialize novel molecules, including small molecules and biologics, that modulate GPCR targets across a range of gastrointestinal diseases and other therapeutic areas.

We will use our proprietary GPCR-focused structure-based drug design capabilities to support the discovery of potential novel agents directed towards multiple GPCR targets nominated by Takeda. Takeda has exclusive global rights to develop and commercialize therapeutic agents for each novel target.